A Phase 3 interventional study of Ferric Carboxymaltose and Placebo in Heart Failure and Iron-deficiency, sponsored by American Regent, Inc.. Completed at 346 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing ferric carboxymaltose in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. ferric carboxymaltose · Heart Failure.
Among the 12 studies testing ferric carboxymaltose in Heart Failure, this one has the largest enrollment, is one of 5 that started in 2017, is one of 4 in phase 3, and was the 6th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →1 of the 12 studies testing ferric carboxymaltose in Heart Failure is open now, in 1 country. Recruiting first, the newest first:
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,065 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 46 across the 12 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
Daiichi Sankyo has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing ferric carboxymaltose in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency
This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) distance for patients in heart failure with iron deficiency.
After an initial screening period of up to 28 days, eligible participants will be stratified by region and randomized in a 1:1 ratio to FCM or placebo for treatment.
Study drug administration will occur on Day 0 and Day 7 (±2) as an undiluted slow IV push, with additional study visits planned at 3 month intervals, and additional dosing administered every 6 months as applicable. In a subset of sites, a sub-study will be conducted to characterize serum phosphate levels over time in participants with heart failure and iron deficiency after dosing with FCM. For all participants, hematology, ferritin, and transferrin saturation (TSAT), with appropriate safety evaluations, to determine additional treatment, will occur at 6 month intervals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Reduced . Assessment must be performed at least 12 weeks after major cardiac surgical intervention including coronary artery bypass graft (CABG), valvular repair/replacement, or cardiac resynchronization therapy (CRT) device implantation.
a. Left ventricular ejection fraction ≤ 40% obtained during the screening visit OR either of the following i. Historical value of ejection fraction ≤ 40% within 24 months of screening visit ii. Historical value of ejection fraction ≤ 30% within 36 months of screening visit
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices.
Drug: Ferric Carboxymaltose
Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.
Drug: Placebo
Intravenous Iron
Also known as: Injectafer, Ferinject
Normal Saline Solution
Also known as: Saline solution
Number of Deaths
The number of participants who died out of the total treated group.
Time frame: 1 year
Number of Hospitalizations for Heart Failure
The number of participants who were hospitalized for heart failure out of the total treated group.
Time frame: 1 year
Change in 6MWT (Six Minute Walk Test) Distance
The change in meters walked at baseline compared to 6 months later.
Time frame: 6 months
| Milestone | Ferric Carboxymaltose | Placebo |
|---|---|---|
| Started | 1532 | 1533 |
| Completed | 1123 | 1121 |
| Not completed | 409 | 412 |
| Withdrew: Death | 354 | 367 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Withdrawal by subject | 48 | 41 |
The number of participants who died out of the total treated group.
| Participants | Ferric Carboxymaltose | Placebo |
|---|---|---|
| Number of Deaths | 131 | 158 |
The number of participants who were hospitalized for heart failure out of the total treated group.
| Participants | Ferric Carboxymaltose | Placebo |
|---|---|---|
| Number of Hospitalizations for Heart Failure | 297 | 332 |
The change in meters walked at baseline compared to 6 months later.
| unit of measure in meters | Ferric Carboxymaltose | Placebo |
|---|---|---|
| Change in 6MWT (Six Minute Walk Test) Distance | 8.179 ± 59.963 | 3.979 ± 58.896 |
Collected over 67.5 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Carboxymaltose | 354/1,532 (23.1%) | 413/1,532 (27%) | 424/1,532 (27.7%) |
| Placebo | 367/1,533 (23.9%) | 401/1,533 (26.2%) | 412/1,533 (26.9%) |
| Event | Ferric Carboxymaltose | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 57/1532 | 35/1533 |
| Acute kidney injuryRenal and urinary disorders | 46/1532 | 40/1533 |
| COVID-19Infections and infestations | 39/1532 | 37/1533 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 23/1532 | 21/1533 |
| SepsisInfections and infestations | 21/1532 | 13/1533 |
| CellulitisInfections and infestations | 12/1532 | 21/1533 |
| Urinary Tract InfectionInfections and infestations | 17/1532 | 9/1533 |
| HypotensionVascular disorders | 17/1532 | 14/1533 |
| COVID-19 pneumoniaInfections and infestations | 11/1532 | 17/1533 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 16/1532 | 12/1533 |
| Event | Ferric Carboxymaltose | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 57/1532 | 35/1533 |
| Cardiac disordersCardiac disorders | 50/1532 | 52/1533 |
| Acute kidney injuryRenal and urinary disorders | 46/1532 | 40/1533 |
| Nervous system disordersNervous system disorders | 39/1532 | 46/1533 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 44/1532 | 45/1533 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 43/1532 | 35/1533 |
| COVID-19Infections and infestations | 39/1532 | 37/1533 |
| General disorders and administration site conditionsGeneral disorders | 29/1532 | 31/1533 |
| Musculoskeletal and connective tissue disorderMusculoskeletal and connective tissue disorders | 25/1532 | 27/1533 |
| Neoplasms benign, malignant and unspecified (incl systs and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25/1532 | 27/1533 |
| Age, Categorical(Participants) | Ferric Carboxymaltose | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 508 | 525 | 1033 |
| >=65 years | 1024 | 1008 | 2032 |
| Age, Continuous(years) | Ferric Carboxymaltose | Placebo | Total |
|---|---|---|---|
| Mean | 68.57 ± 10.94 | 68.57 ± 11.20 | 68.57 ± 11.07 |
| Sex: Female, Male(Participants) | Ferric Carboxymaltose | Placebo | Total |
|---|---|---|---|
| Female | 506 | 531 | 1037 |
| Male | 1026 | 1002 | 2028 |
| Ethnicity (NIH/OMB)(Participants) | Ferric Carboxymaltose | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 85 | 100 | 185 |
| Not Hispanic or Latino | 1440 | 1424 | 2864 |
| Unknown or Not Reported | 7 | 9 | 16 |
| Race (NIH/OMB)(Participants) | Ferric Carboxymaltose | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 5 | 11 |
| Asian | 19 | 21 | 40 |
| Native Hawaiian or Other Pacific Islander | 6 | 5 | 11 |
| Black or African American | 162 | 160 | 322 |
| White | 1324 | 1325 | 2649 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 13 | 14 | 27 |
| Region of Enrollment(participants) | Ferric Carboxymaltose | Placebo | Total |
|---|---|---|---|
| Hungary | 11 | 17 | 28 |
| United States | 612 | 601 | 1213 |
| Czechia | 14 | 19 | 33 |
| Ukraine | 243 | 217 | 460 |
| Russia | 58 | 65 | 123 |
| New Zealand | 46 | 54 | 100 |
| Canada | 109 | 120 | 229 |
| Latvia | 1 | 3 | 4 |
| Poland | 83 | 87 | 170 |
| Georgia | 88 | 92 | 180 |
| Australia | 59 | 51 | 110 |
| Bulgaria | 195 | 197 | 392 |
| Lithuania | 13 | 9 | 22 |
| Estonia | 0 | 1 | 1 |
| Intent-to-treat Analysis Population(Participants) | Ferric Carboxymaltose | Placebo | Total |
|---|---|---|---|
| Count of participants | 1123 | 1121 | 2244 |
Showing the first 100 of 346 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Feb 2023, 70 months.
Results were first posted in Jul 2024, 1 year 5 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 70 months is above that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose